We have characterized a new clinical strain of *Trichophyton rubrum* highly resistant to terbinafine but exhibiting normal susceptibility to drugs with other mechanisms of action. Resistance to terbinafine in this strain is caused by a missense mutation in the squalene epoxidase gene leading to the amino acid substitution F397L.

Terbinafine, whose target is squalene epoxidase (SE), part of the ergosterol biosynthesis pathway, is used extensively in the treatment of dermatophytosis, a common infection caused by dermatophytes. Nevertheless, the occurrence of terbinafine-resistant clinical isolates is rare, and only one case has been documented and thoroughly investigated (7, 14, 17); the resistance mechanism was identified as a single amino acid substitution in SE. Except for this one case, terbinafine failure in patients suffering from nail infections due to *Trichophyton rubrum* has been shown not to be related to high MICs or resistance development during therapy (1, 9). The same conclusion was drawn by Hofbauer et al. (11) in a veterinary study. In vitro, the frequency of spontaneous resistance of *T. rubrum* to terbinafine is low and it is also difficult to induce resistance (16). Nevertheless, dermatophytes with abnormally low susceptibility to terbinafine do exist (8, 10, 18). Here, we have identified such a clinical strain (NFI5166), originally isolated by C. Burri (Chur, Switzerland), and characterized it at a biological, biochemical, and molecular level.

NFI5166 was tested in comparison with NFI1895, a well-characterized internal reference clinical strain from the Novartis Fungal Index (NFI) collection. MICs against *T. rubrum* were determined in broth microdilution assays based on the CLSI (formerly NCCLS) M38-A protocol (15) as described previously (11). NFI5166 was strongly resistant to terbinafine, with a drug MIC of 64 μg/ml compared to <1 ng/ml for NFI1895 (Table 1). This drug MIC was even higher than those for the previously analyzed terbinafine-resistant strains NFI5146 to NFI5150 (4 μg/ml) (14), which were isolated from a different patient. NFI5166 was also strongly (>100-fold) cross-resistant to other SE inhibitors tested (naftifine, butenafine, and tolnaftate). Susceptibility to fluconazole and griseofulvin was similar to that of the wild-type strain NFI1895. The MIC of itraconazole for NFI5166 was 64-fold higher than that for NFI1895 but was similar to those seen for other wild-type strains tested (data not shown). Systematic cross-resistance to SE inhibitors suggested a target-based mechanism of resistance. Preparation of microsomes and assay of SE activity were performed as previously described (4, 6, 7). NFI5166 SE-specific activity of 0.013 mmol/h/mg protein was about threefold lower than for strains NFI1895, NFI15146, and NFI15150 (7). The 50% inhibitory concentration of terbinafine was 1.3 μg/ml for SE from NFI5166 versus 0.006 μg/ml for the microsomal activity of NFI1895. These results reinforced the hypothesis that an alteration of SE was involved in the resistance phenotype of NFI5166.

To further characterize the strain, NFI5166 SE was cloned and sequenced as described previously (17). The SE sequence from NFI5166 contained a missense substitution, 1189TTC→ATT (F397L). The SE-specific activity of 0.013 mmol/h/mg protein was about threefold lower than for NFI5166 versus 0.006 μg/ml for NFI1895 (16). The MIC of itraconazole for NFI5166 was 0.04 μg/ml compared to 0.004 μg/ml for NFI5182. Overall, the susceptibility pattern of NFI5166 compared to that of wild-type NFI5182 was 100-fold lower than the wild-type, and the resistance phenotype was consistent with that of other clinical isolates.

The F397L substitution identified in NFI5166 is very close to F397L in the reference strain NFI1895, which is not resistant to terbinafine. The F397L substitution is also present in the terbinafine-resistant strain NFI5146 to NFI5150, which are not resistant to terbinafine. This suggests that the F397L substitution is not responsible for the resistance to terbinafine in these strains.

**TABLE 1.** MICs of several antifungals against *T. rubrum* NFI5166 and the reference strain NFI1895 determined using the broth macrodilution method.

<table>
<thead>
<tr>
<th>Compound</th>
<th>NFI5166</th>
<th>NFI1895</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terbinafine</td>
<td>64</td>
<td>0.0002</td>
</tr>
<tr>
<td>Naftifine</td>
<td>64</td>
<td>0.04</td>
</tr>
<tr>
<td>Butenafine</td>
<td>1</td>
<td>0.0005</td>
</tr>
<tr>
<td>Tolnaftate</td>
<td>0.25</td>
<td>0.0002</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>0.5</td>
<td>0.008</td>
</tr>
<tr>
<td>Griseofulvin</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

* Corresponding author. Mailing address: Infectious Diseases, Room 8654, Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, MA 02139. Phone: (617) 871 3142. Fax: (617) 871 7047. E-mail: colin.osborne@novartis.com.
† Present address: Infection and Immunity, University of Wales College of Medicine, Henry Wellcome Research Institute, Heath Park, Cardiff CF14 4XX, United Kingdom.
‡ Present address: Department of Dermatology, Hospital of Beau- mont CHUV, 1011 Lausanne, Switzerland.
§ Present address: Infectious Diseases, Novartis Institutes for Bio- medical Research, Inc., Cambridge, MA 02139.
we used the model that of NFI5166, with resistance to SE inhibitors and normal (broth microdilution method [16]; data not shown) was similar to substitution; /H18528 (wild-type residues are underlined), affecting the susceptibility of fungi to terbinafine, were found. Key: *, identical between sequences, :, conserved substitution; -, semiconserved substitution; _; wild type.

To further demonstrate that this amino acid substitution is at least partly responsible for the resistance phenotype of NFI5166 and NFI5182-06, we used the model Candida albicans SE cloned into the expression vector pYES2 and Saccharomyces cerevisiae as the recipient organism (17). The mutation F402L, corresponding to the alteration F397L identified in SE from NFI5166 (Fig. 1), was introduced into the C. albicans SE sequence (17) by use of a QuikChange site-directed mutagenesis kit (Stratagene). After transformation of S. cerevisiae INVSc1 and selection on medium lacking uracil, glucose was replaced by galactose to induce the expression of C. albicans SE (5). A microdilution assay using a 96-well plate (Greiner) replaced by galactose to induce the expression of INVSc1 and selection on medium lacking uracil, glucose was

The main features of NFI5166 are very similar to those of the previously reported set of resistant isolates from a single patient, NFI5146 to NFI5150, which can be considered a single strain (7, 14, 17). Both the new isolate, NFI5166, and the strain reported earlier, NFI5146 (the baseline isolate), are cross-resistant to all tested SE inhibitors, are normally susceptible to other antifungals with a different mode of action, have microsomal SE activity much less sensitive to terbinafine than wild-type strains, and contain single amino acid substitutions in the same domain of

So far our analyses have revealed that terbinafine resistance in T. rubrum is only connected to amino acid substitutions in SE. However, this does not preclude other resistance mechanisms. The occurrence of multiple antifungal resistance mechanisms within the same organism is well established (3, 13, 19, 20). Nevertheless, resistance to terbinafine in NFI5166 might be pleiotropic, since this strain is more resistant than NFI5182-06, which carries the same SE mutation.

In conclusion, alteration of the target of terbinafine in T. rubrum seems to be the predominant resistance mechanism in this organism. However, since the frequency of resistance of T. rubrum to terbinafine is very low, it appears unlikely that resistance to terbinafine therapy will become a significant clinical problem.

Nucleotide sequence accession number. The complete sequence data for NFI5166 SE have been assigned GenBank accession number DQ060522.

**REFERENCES**


**TABLE 2. MIC of terbinafine required to reach 90% growth inhibition of S. cerevisiae INVSc1, transformed with various CaSE constructs, in liquid RPMI 1640 medium**

<table>
<thead>
<tr>
<th>Construct</th>
<th>Mutation</th>
<th>90% MIC (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>pYES2</td>
<td></td>
<td>4–8</td>
</tr>
<tr>
<td>CaSE</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td>CaSE</td>
<td>F402L</td>
<td>&gt;128</td>
</tr>
</tbody>
</table>
terbinafine, ketoconazole and itraconazole against dermatophytes and non-
dermatophytes, and in vitro evaluation of combination antifungal activity.
Microsporum canis and other dermatophyte isolates from veterinary infec-
tions during therapy with terbinafine or griseofulvin. Med. Mycol. 40:179–
183.
12. Leber, R., S. Fuchsbichler, V. Klobucnikova, N. Schweighofer, E. Pitters,
K. Wohlfarter, M. Lederer, K. Landl, C. Ruckenstuhl, I. Hapala, and F.
Turnowsky. 2003. Molecular mechanism of terbinafine resistance in Saccha-
Dis. 36:313–334.
14. Mukherjee, P. K., S. D. Leidich, N. Isham, I. Leitner, N. S. Ryder, and M. A.
Ghannoum. 2003. Clinical Trichophyton rubrum strain exhibiting primary
15. National Committee for Clinical Laboratory Standards. 2000. Reference
method for broth dilution antifungal susceptibility testing of conidium-form-
ing filamentous fungi. Approved standard M38-A. NCCLS, Wayne, PA.
analysis of the ability of Trichophyton rubrum to become resistant to terbin-
substitution in Trichophyton rubrum squalene epoxidase associated with re-
18. Perea, S., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2001. Compar-
ison of in vitro activities of voriconazole and five established antifungal
agents against different species of dermatophytes using a broth macrodilu-